Categories Uncategorized

Researchers Find That Disrupted Sleep Could Result in Early Death

A recent study has found a clear link between a higher risk of dying from illnesses of the heart and blood vessels and the duration and frequency of unconscious wakefulness throughout night-time sleep.

The researchers discovered that in comparison with the general female population, women who underwent unconscious wakefulness for long periods of time had a higher risk of dying from a cardiovascular ailment. The research findings were reported in the “European Heart Journal.”

The study, which had 8,001 male and female participants, could not find a clear link in males as their cardiovascular death risk only grew by a quarter when compared to the general male population.

The researchers describe unconscious wakefulness as a normal part of sleep. It is also referred to as cortical arousal and is said to occur rather spontaneously. It’s part of the ability of an individual’s body to respond to situations that could possibly be dangerous, such as breathing becoming obstructed. Other triggers include noise, light, temperature, trauma, limb movements and pain.

An associate professor for the cardiology department at the Maastricht University Medical Center, Dominik Linz explained that while an individual may consciously become aware of their environment, depending on the strength of the arousal, which usually doesn’t happen. This is why, despite the sleep fragmentation, individuals may feel tired or exhausted in the morning but will not be cognizant of the arousals.

Prior research has demonstrated that sleep duration, whether too long or too short, is linked to a higher risk of death from cardiovascular illnesses as well as other causes.

This recent research was conducted in collaboration with a group of researchers from the University of Adelaide’s School of Electrical and Electronic Engineering. The group was led by Associate professor Matthias Baumert.

The researchers examined data obtained from sleep monitors worn throughout the night by women and men who had taken part in three separate studies, including the Sleep Heart Health Study, the Study of Osteoporotic Fractures and the Osteoporotic Fractures in Men Sleep Study. The participants were followed up for a period of six to eleven years.

Linz noted that it was unclear why there was a difference between women and men in the associations but speculated that the body’s response to arousal or triggers that caused an arousal could explain the increased risk of cardiovascular death in women. He added that advising patients to practice good sleep hygiene while also minimizing noise pollution at night could help decrease the arousal burden.

The research spotlight isn’t only being put on complications resulting from sleep disruptions. Other companies are looking into different health complications, and Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) has succeeded in designing techniques and technology that can help clinicians get a better view of cancerous tissues during surgical procedures.

NOTE TO INVESTORS: The latest news and updates relating to Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation

Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.…

1 day ago

Oncolytic Virus Therapy is Set to Transform Cancer Care

Enormous resources are being channeled into studying different ways to support the immune system in its fight…

1 day ago

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within…

2 days ago

Study Finds That Marijuana Legalization Lowers Crime Rates

David Eby, the Premier of British Columbia, has revealed that a wide range of American healthcare workers,…

2 days ago

Earth Science Tech Inc. (ETST) Builds Telehealth, Pharmacy Links in Evolving Digital Care

Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer…

3 days ago

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline

High-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology. Soligenix…

4 days ago